|
1
|
Lennon AM, Wolfgang CL, Canto MI, et al:
The early detection of pancreatic cancer: What will it take to
diagnose and treat curable pancreatic neoplasia? Cancer Res.
74:3381–3389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu L, Yuan H, Guo C, et al: Zearalenone
induces apoptosis and necrosis in porcine granulosa cells via a
caspase-3- and caspase-9-dependent mitochondrial signaling pathway.
J Cell Physiol. 227:1814–1820. 2012. View Article : Google Scholar
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaib Y, Davila J and El-Serag H: The
epidemiology of pancreatic cancer in the United States: changes
below the surface. Aliment Pharmacol Ther. 24:87–94. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sultana A, Smith CT, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer.
J Clin Oncol. 25:2607–2615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
8
|
Liu L, Chen B, Qin S, et al: A novel
histone deacetylase inhibitor Chidamide induces apoptosis of human
colon cancer cells. Biochem Biophys Res Commun. 392:190–195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong M, Ning ZQ, Xing PY, et al: Phase I
study of chidamide (CS055/HBI-8000), a new histone deacetylase
inhibitor, in patients with advanced solid tumors and lymphomas.
Cancer Chemother Pharmacol. 69:1413–1422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Pan DS, Shan S, et al: Non-toxic
dose chidamide synergistically enhances platinum-induced DNA damage
responses and apoptosis in non-small-cell lung cancer cells. Biomed
Pharmacother. 68:483–491. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Chen B, Qin S, et al: A novel
histone deacetylase inhibitor Chidamide induces apoptosis of human
colon cancer cells. Biochem Biophys Res Commun. 392:190–195. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Guo Y, Fu M, et al: Antitumor
activity of Chidamide in hepatocellular carcinoma cell lines. Mol
Med Rep. 5:1503–1508. 2012.PubMed/NCBI
|
|
13
|
Ning ZQ, Li ZB, Newman MJ, et al:
Chidamide(CS055/HBI-8000): a new histone deacetylase inhibitor of
the benzamide class with antitumor activity and the ability to
enhance immune cell-mediated tumor cell cytotoxicity. Cancer
Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
|
|
14
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiao Z, Ren S, Li W, et al: Chidamide, a
novel histone deacetylase inhibitor, synergistically enhances
gemcitabine cytotoxicity in pancreatic cancer cells. Biochem
Biophys Res Commun. 434:95–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qiao Z, Ren S, Li W, et al: Chidamide, a
novel histone deacetylase inhibitor, synergistically enhances
gemcitabine cytotoxicity in pancreatic cancer cells. Biochem
Biophys Res Commun. 434:95–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yen MC, Weng TY, Chen YL, et al: An HDAC
inhibitor enhances cancer therapeutic efficiency of RNA polymerase
III promoter-driven IDO shRNA. Cancer Gene Ther. 20:351–357. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ning Z-Q, Li Z-B, Newman MJ, et al:
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of
the benzamide class with antitumor activity and the ability to
enhance immune cell-mediated tumor cell cytotoxicity. Cancer
Chemother Pharmacol. 69:901–909. 2012. View Article : Google Scholar
|
|
20
|
Fiandalo MV and Kyprianou N: Caspase
control: protagonists of cancer cell apoptosis. Exp Oncol.
34:165–175. 2012.PubMed/NCBI
|
|
21
|
Yang J, Liu X, Bhalla K, et al: Prevention
of apoptosis by Bcl-2: release of cytochrome c from mitochondria
blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siu WP, Pun PB, Latchoumycandane C and
Boelsterli UA: Bax-mediated mitochondrial outer membrane
permeabilization (MOMP), distinct from the mitochondrial
permeability transition, is a key mechanism in diclofenac-induced
hepatocyte injury: Multiple protective roles of cyclosporin A.
Toxicol Appl Pharmacol. 227:451–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohtsuka T, Buchsbaum D, Oliver P, Makhija
S, Kimberly R and Zhou T: Synergistic induction of tumor cell
apoptosis by death receptor antibody and chemotherapy agent through
JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elmore S: Apoptosis: a review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang WJ, Liang YC, Chuang SE, et al:
NBM-HD-1: A novel histone deacetylase inhibitor with anticancer
activity. Evid Based Complement Alternat Med. 2012:7814172012.
View Article : Google Scholar
|
|
26
|
Ohashi K, Nemoto T, Eishi Y, Matsuno A,
Nakamura K and Hirokawa K: Expression of the cyclin dependent
kinase inhibitor p21WAF1/CIP1 in oesophageal squamous cell
carcinomas. Virchows Arch. 430:389–395. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai L, Liu Y, Liu J, et al: A novel
cyclinE/cyclinA-CDK inhibitor targets p27Kip1
degradation, cell cycle progression and cell survival: implications
in cancer therapy. Cancer Lett. 333:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hoefer J, Schäfer G, Klocker H, et al:
PIAS1 is increased in human prostate cancer and enhances
proliferation through inhibition of p21. Am J Pathol.
180:2097–2107. 2012. View Article : Google Scholar : PubMed/NCBI
|
